Combatting Corruption and Promoting Equity in the Health Sector
1.Svensson, Jakob. 2005. "Eight Questions About Corruption". Journal of Economic Perspectives, 19(3).
2. Paul M. Heywood and Jonathan Rose, “’Close but No Cigar’: The Measurement of Corruption.” Journal of Public Policy vol. 34, no. 3 (2014).
1. Jillian Clare Kohler, Tomas Chang Pico, Taryn Vian, Tim K. Mackey. “The Global Wicked Problem of Corruption and Its Risks for Access to HIV/AIDS Medicines”. Clinical Pharmacology & Therapeutics 104(6) August 2018.
2. Anne Paschke, Deirdre Dimancesco, Taryn Vian, Jillian C Kohler & Gilles Forte. “Increasing transparency and accountability in national pharmaceutical systems”. Bulletin of the World Health Organization. 2018;96(11):782-791
3. Access to Medicine Index 2018, Market Influence & Compliance, p.48-55
4. Genovese L, Edwards D. Why It Matters - Pharmaceutical Compliance, Anti-Corruption and Access to Medicine.; 2017
5. Transparency International UK, Corruption in the pharmaceutical sector
Walkowiak H, Hafner T, Putter S.J. 2018. Strengthening Governance in Pharmaceutical Systems:A Compendium of Country Case Studies. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health. (p 22-24)
1. Seiter, A. (2010). A practical approach to pharmaceutical policy. The World Bank.
2. Diack, A., Seiter, A., Hawkins, L., & Dweik, I. S. (2010). Assessment of governance and corruption in the pharmaceutical sector: Lessons learned from low and middle income countries.
3. Hussman, K. (2011). Vulnerabilities to Corruption in the Health Sector: Perspectives from Latin American sub-sytems for the Poor. United Nations Development Programme. Panama.